Novartis/$NVS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Novartis

Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Ticker

$NVS
Sector

Primary listing

NYSE

Employees

75,883

Headquarters

Basel, Switzerland

Novartis Metrics

BasicAdvanced
$256B
19.13
$6.85
0.56
$2.60
1.98%

What the Analysts think about Novartis

Analyst ratings (Buy, Hold, Sell) for Novartis stock.

Bulls say / Bears say

Novartis raised its full-year 2025 earnings outlook, increasing its core operating income growth target to the low-teens range from the previous low-double-digits, following a strong Q2. (Reuters)
In June 2025, Novartis announced that Pluvicto’s late-stage PSMAddition trial achieved its primary goal by demonstrating a clinically meaningful improvement in progression-free survival for patients with metastatic hormone-sensitive prostate cancer, supporting a possible regulatory expansion in H2 2025. (Reuters)
Novartis received a positive CHMP opinion for Piqray in HR+/HER2- advanced breast cancer patients with PIK3CA mutations. Phase III data showed nearly double median progression-free survival, 11.0 months versus 5.7 months, significantly strengthening its oncology portfolio. (Reuters)
Sales of Cosentyx fell short of expectations, and increased generic competition reduced Q2 growth by two percentage points, showing ongoing challenges in Novartis’s established brands. (Reuters)
Novartis could face civil or criminal penalties after admitting data manipulation in its Zolgensma gene therapy program, exposing it to legal and reputational risks. (Reuters)
Pursuing both a $10 billion share buyback and a $23 billion U.S. manufacturing expansion could pressure Novartis’s free cash flow and reduce its financial flexibility for future R&D. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.

Novartis Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Novartis Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NVS

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

No upcoming events
FAQs